We are live on
!
Find out more
BCA
Benchmark Capital Advisors Portfolio holdings
AUM
$101M
Turnover
16.91%
1-Year Est. Return
0.8%
This Fund
S&P 500
This Quarter
Est. Return
+9.68%
1 Year Est. Return
-0.8%
3 Year Est. Return
+29.53%
5 Year Est. Return
+43.22%
10 Year Est. Return
–
AUM
$139M
AUM Growth
+$9.62M
(+7.4%)
Cap. Flow
+$2.42M
Cap. Flow
% of AUM
1.74%
Top 10 Holdings %
Top 10 Hldgs %
27.84%
Holding
157
New
14
Increased
39
Reduced
52
Closed
19
Avg Time Held
0.2
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vodafone
VOD
|
+$2.49M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.34M |
| 3 |
GEN MOTORS CORP
GM
|
+$2.05M |
| 4 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$1.37M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ligand Pharmaceuticals
LGND
|
+$1.98M |
| 2 |
Howard Hughes
HHH
|
+$1.7M |
| 3 |
DNY
DONNELLEY R R & SONS CO
DNY
|
+$1.39M |
| 4 |
Newmont
NEM
|
+$860K |
| 5 |
Corning
GLW
|
+$834K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 20.67% |
| 2 | Energy | 14.21% |
| 3 | Technology | 10.78% |
| 4 | Healthcare | 9.81% |
| 5 | Consumer Discretionary | 9.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Coca-Cola
KO
$404B
| $830K | 0.6% |
21,900
+15,900
| +265% | +$629K |
2013 Q2
1 quarter
|
|
52
DELISTED
Du Pont De Nemours E I
DD
| $789K | 0.57% |
14,189
-369
| -3% | -$20.2K |
2013 Q2
1 quarter
|
|
53
Terex
TEX
$5.83B
| $780K | 0.56% |
23,200
-200
| -0.9% | -$6.06K |
2013 Q2
1 quarter
|
|
54
ConocoPhillips
COP
$176B
| $775K | 0.56% |
11,150
+400
| +4% | +$26.7K |
2013 Q2
1 quarter
|
|
|
SSW.PRD
55
DELISTED
Seaspan Corporation 7.95% Series D Cumulative Redeemable Perpetual Preferred Shares
SSW.PRD
| $767K | 0.55% |
30,400
+200
| +0.7% | +$5.13K |
2013 Q2
1 quarter
|
|
56
iShares Mortgage Real Estate ETF
REM
$453M
| $763K | 0.55% |
15,900
+2,500
| +19% | +$122K |
2013 Q2
1 quarter
|
|
57
Tapestry
TPR
$23.8B
| $758K | 0.54% |
13,900
+900
| +7% | +$49.6K |
2013 Q2
1 quarter
|
|
58
Healthpeak Properties
DOC
$13.1B
| $735K | 0.53% |
19,709
+110
| +0.6% | +$4.29K |
2013 Q2
1 quarter
|
|
59
Starwood Property Trust
STWD
$4.61B
| $716K | 0.51% |
37,020
-1,054
| -3% | -$21.2K |
2013 Q2
1 quarter
|
|
60
iShares S&P 100 ETF
OEF
$20.4B
| $709K | 0.51% |
9,480
-6,700
| -41% | -$504K |
2013 Q2
1 quarter
|
|
|
VNOD.CL
61
DELISTED
VORNADO REALTY LP 7.875% PUB INCOME NTS DUE 10/01/2039
VNOD.CL
| $687K | 0.49% |
26,185
-200
| -0.8% | -$5.27K |
2013 Q2
1 quarter
|
|
62
Bausch Health
BHC
$2.36B
| $678K | 0.49% |
+6,500
| New | +$633K |
2013 Q3
0 quarters
|
|
63
Annaly Capital Management
NLY
$13.7B
| $677K | 0.49% |
14,625
-75
| -0.5% | -$3.53K |
2013 Q2
1 quarter
|
|
64
MetLife Inc Floating Rate Series A
MET.PRA
$500M
| $674K | 0.48% |
29,300
-1,000
| -3% | -$23.9K |
2013 Q2
1 quarter
|
|
65
Galectin Therapeutics
GALT
$365M
| $653K | 0.47% |
65,500
+45,500
| +228% | +$307K |
2013 Q2
1 quarter
|
|
66
Vale
VALE
$55.6B
| $612K | 0.44% |
39,200
-2,000
| -5% | -$29.6K |
2013 Q2
1 quarter
|
|
|
DPO
67
DELISTED
DOW ENHANCED PREMIUM & INCOME FUND, INC COM
DPO
| $601K | 0.43% |
51,100
+1,000
| +2% | +$12.2K |
2013 Q2
1 quarter
|
|
68
DELISTED
Vertex Energy, Inc
VTNR
| $591K | 0.42% |
195,669
| – | – |
2013 Q2
1 quarter
|
|
69
Abundia Global Impact Group
AGIG
$36.6M
| $588K | 0.42% |
16,219
-64
| -0.4% | -$2.44K |
2013 Q2
1 quarter
|
|
70
Pembina Pipeline
PBA
$29.1B
| $577K | 0.41% |
17,400
| – | – |
2013 Q2
1 quarter
|
|
|
MCR
71
DELISTED
MFS Charter Income Trust
MCR
| $575K | 0.41% |
64,300
| – | – |
2013 Q2
1 quarter
|
|
72
ArcelorMittal
MT
$47.4B
| $554K | 0.4% |
17,712
| – | – |
2013 Q2
1 quarter
|
|
73
American International
AIG
$42.2B
| $535K | 0.38% |
11,000
| – | – |
2013 Q2
1 quarter
|
|
74
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $517K | 0.37% |
37,500
| – | – |
2013 Q2
1 quarter
|
|
75
Morgan Stanley Series A Preferred Stock
MS.PRA
$762M
| $515K | 0.37% |
26,360
| – | – |
2013 Q2
1 quarter
|
|
Similar funds
OIMU
7A
JCP
DCM
BCEM
QAM
CFA
BPV
Benchmark Capital Advisors's Q3 2013 Portfolio in Review
As of Q3 2013, Benchmark Capital Advisors held 157 positions worth $139M, up 7.4% from $130M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Benchmark Capital Advisors's Q3 2013 filing shows 14 new, 39 increased, 52 reduced and 19 closed positions. Its largest new stake was Bristol-Myers Squibb: 53,400 shares worth $2.47M. The largest sale was Ligand Pharmaceuticals, an estimated $1.98M.
By sector, the portfolio is most concentrated in Miscellaneous at 21% of assets, down from 24% a quarter earlier, followed by Energy and Technology.
- Benchmark Capital Advisors's largest Q3 2013 buy was Bristol-Myers Squibb: 53,400 shares worth $2.47M.
- Benchmark Capital Advisors added most to Vodafone in Q3 2013, an estimated $2.49M increase.
- Benchmark Capital Advisors's biggest Q3 2013 reduction was Howard Hughes, cutting an estimated $1.7M.
- Benchmark Capital Advisors fully exited Ligand Pharmaceuticals in Q3 2013, selling an estimated $1.98M.
- Benchmark Capital Advisors's ten largest holdings make up 28% of its $139M portfolio in Q3 2013.
- Benchmark Capital Advisors opened 14 new positions and closed 19 in Q3 2013.
- Benchmark Capital Advisors's portfolio value rose 7.4% quarter-over-quarter to $139M.
Based on Benchmark Capital Advisors's 13F filing for Q3 2013, filed 23 Oct 2013.